How Do I Phase Testing and Validation Investments Over 12–24 Months?

Key Takeaways

Most food manufacturers do not have a testing and validation budget problem, they have a sequencing and prioritization problem.
A 12 to 24 month phased plan lets you tackle the highest consequence gaps first, spread capital predictably, and build audit-defensible documentation instead of scrambling after incidents.
Tier 1 (routine testing), Tier 2 (EMP troubleshooting), and Tier 3 (high-risk validation) need to sit in a single governed roadmap that aligns with CFIA, Health Canada, FSMA, and GFSI expectations.
One-time validation projects without governance, revalidation triggers, or accredited methods create audit gaps, duplicate spend, and data that may not stand up in a CFIA investigation or a major retailer audit.
Consolidating on ISO 17025 accredited labs, clarifying governance between QA, operations, and finance, and building annual review cycles turns validation from a reactive project into a standing program with a clear financial logic.

Article at a Glance

Phasing testing and validation investments over 12 to 24 months is not a cost-cutting tactic. It is a way to align microbiology work with regulatory risk, operational realities, and capital planning so QA, operations, and finance are working from the same roadmap. Instead of waiting for CFIA findings, retailer demands, or internal incidents to dictate priorities, leaders can decide in advance which kill steps, EMP gaps, and shelf life questions need Tier 3 attention and when.

This approach rests on a simple structure. Tier 1 covers routine verification testing. Tier 2 covers EMP troubleshooting and investigation work. Tier 3 covers high-risk validation studies that define the boundaries of safe operation. A credible roadmap connects all three, with high-hazard processes and regulatory deadlines driving the early phases.

The financial case is not abstract. One recall, licence suspension, or delisting from a key customer will usually cost more than several years of structured testing and validation spend. A phased program does not guarantee that those events will never occur, but it can lower their likelihood and significantly strengthen the company’s position when regulators, auditors, or buyers ask hard questions.

Why Testing and Validation Spend Goes to the Wrong Places

Most mid-sized manufacturers spend real money on microbiology. The issue is where and when that money lands.

The first misallocation pattern is heavy spending on routine release testing while underinvesting in the validation that gives those results meaning. A finished product micro panel on every lot looks rigorous on paper. If the underlying kill step has never been formally validated, the organisation is effectively testing products without clear evidence that the process can deliver the intended lethality.

The second pattern is fragmented, demand-driven commissioning. Studies are launched when a retailer, export market, or auditor asks for them, not when the risk profile of the portfolio demands them. A kill step study for one product, a rushed shelf life study for a new customer, a one-off EMP investigation after a positive result. Each study solves an immediate problem, but they rarely add up to a coherent validation program.

The result is predictable. Budgets creep upward without a clear architecture. Documentation grows in volume but not in defensibility. QA teams carry the burden of managing multiple labs, methods, and reports that do not fit together cleanly at audit time.

The Real Cost of Getting Validation Wrong

Underinvested or poorly structured validation programs show up in financial statements and risk registers, not just in audit reports.

Recalls, Enforcement, and Delistings

A serious recall for a high-risk product category brings direct costs, including logistics, disposal, crisis communications, and overtime. The bigger hits usually come from:

Retailer penalties and chargebacks.
Lost shelf space and requalification costs.
Increased sampling and corrective action requirements imposed by customers.
Management and legal time diverted to incident handling.

Under the Safe Food for Canadians Regulations (SFCR), CFIA can suspend licences and issue administrative monetary penalties when non-compliance is identified. Those actions carry both direct and reputational costs that extend well beyond the incident period.

Reactive Spend and Working Capital

Reactive validation spend tends to show up when a plant can least afford distraction. A rushed kill step study during a product hold. An emergency EMP redesign after a Zone 1 positive. A shelf life study commissioned because a retailer suddenly demands documentation for a product that has been on the market for years.

In each case, the cost per study is higher because timelines are compressed and plant disruption is greater. Working capital is consumed at the point of maximum stress. A phased program amortizes these costs across a planned 12 to 24 month window where operations can schedule trials and finance can plan for cash impact.

Insurance and Exit Value

Product liability insurers and sophisticated buyers increasingly ask to see evidence that validation programs are current and aligned with regulatory expectations. Gaps in kill step validation, weak EMP trend data, or reliance on non-accredited methods can translate into:

Higher insurance premiums or more restrictive coverage terms.
More aggressive representations, warranties, and indemnities in transaction documents.
Price adjustments or holdbacks during sale or investment negotiations.

For owners contemplating a sale or refinancing event in the next three to five years, these issues are not theoretical. They influence valuations and deal terms in ways that are hard to reverse once a due diligence report is written.

Why One-Time Validation Projects Fail

Treating validation as a one-off project is structurally misaligned with how food safety risk behaves.

Formulations shift, equipment ages, capacities increase, and regulatory expectations evolve. A kill step study run on a line seven years ago may have used different inoculation levels, surrogates, or process parameters than current Health Canada or CFIA guidance expects. A shelf life study completed before a change in packaging suppliers may not reflect the barrier properties or abuse conditions of the product now on shelves.

Static Studies in a Dynamic System

When validation is framed as a project with a finish line, the study becomes a static artifact. It answers a specific question at a point in time. Without clear revalidation triggers and a review cycle, the organisation begins to treat that document as permanent proof of control.

Auditors and regulators do not see it that way. Under GFSI-recognized schemes and FSMA Preventive Controls, for example, they typically expect to see:

Defined revalidation triggers (such as formulation changes, process parameter shifts, or new scientific information).
Evidence that changes have been assessed against those triggers.
Justification for why validation remains current or why a new study was commissioned.

Validation packages that cannot connect their conclusions to current operating conditions are one of the most common failure points in detailed audits.

Fragmented Labs and Methods

Another common failure mode is vendor sprawl. Plants accumulate multiple lab relationships over time, each serving different product lines, customers, or projects. Methods vary, detection limits differ, and accreditation scopes are inconsistent.

When it is time to trend data or present a unified view of control, the organisation discovers that:

Results from different labs are not directly comparable.
Some methods are not accredited for the matrices or analytes used in critical studies.
Key pieces of evidence cannot be tied to a single, coherent quality system.

The visible cost is duplicate testing. The hidden cost is the time senior QA people spend reconciling conflicting results or commissioning repeat work with an accredited lab because a customer or auditor rejects prior data.

What a Modern, Phased Program Actually Looks Like

A modern testing and validation program is not just more testing. It is an integrated system built on three tiers, with governance that keeps them aligned to risk and regulatory expectations.

The Three Tiers in One Roadmap

Tier 1 Routine verification
Finished product micro panels, incoming ingredient testing, and in-process indicators. These tests confirm controls are operating as designed.
Tier 2 EMP and investigations
Environmental swabbing by zone, routine trend analysis, intensified sampling during investigations, and corrective action verification. This tier links environmental performance to product risk.
Tier 3 High-risk validation
Kill step validation, microbial challenge studies, shelf life modeling, hurdle validation (pH and water activity), and ICMSF-based sampling plan design. This work establishes that the process and product can meet safety objectives under defined conditions.

All three tiers are required in a mature program. The phasing question is how to allocate limited investment over 12 to 24 months so that Tier 3 work in high-hazard areas is not starved while Tier 1 spend grows on low-risk lines.

Risk Tiers by Product and Process

Leadership teams need a clear view of risk by product and process category before debating phasing or budget. A simplified view is shown below.

Product / Process Category	Primary Hazard	Typical Tier 3 Focus	Illustrative Regulatory Reference
Low-moisture RTE (nuts, snacks, spices)	Salmonella	Kill step validation for roasting or other lethality steps	CFIA, Health Canada guidance, FSMA Preventive Controls
Refrigerated RTE deli meats and salads	Listeria monocytogenes	Shelf life validation, EMP alignment, Listeria control verification	Health Canada Listeria Policy (most recent version)
Acidified and fermented products	E. coli O157, Salmonella	pH and water activity hurdle validation, process challenge studies	CFIA and Codex references for acidified and fermented
Shelf-stable low-acid canned foods (LACF)	Clostridium botulinum	Scheduled process validation, container integrity and sterility	CFIA and Health Canada expectations for LACF
Fresh produce and sprouts	E. coli, Salmonella, Listeria	Water quality validation, post-harvest treatment studies	CFIA and FSMA Produce Safety Rule

This table is a starting frame, not a substitute for product-specific assessment. Actual validation needs depend on formulation, process, packaging, distribution, consumer group, and jurisdiction.

In a phased plan, products and processes with the highest severity and clearest regulatory precedents should usually receive Tier 3 investment in the first 12 months. Expanding routine panels on lower-risk SKUs should come after those core risks are addressed.

Why ISO 17025 Accreditation is Non-Negotiable for Critical Evidence

ISO 17025 accreditation confirms that a laboratory’s management system and technical competence for specific methods have been assessed against an international standard. For manufacturers, two questions matter:

Is the lab accredited for the specific method, matrix, and analyte used in the study?
Will regulators, auditors, and customers accept data from that method as part of a validation package?

Accreditation is always scope-specific. A lab may be accredited for generic indicator testing but not for Listeria confirmation, spore-former enumeration, or water activity on the relevant matrices. Using non-accredited methods for Tier 3 work risks having key studies rejected, which usually leads to:

Repeat work with an accredited lab at additional cost.
Delayed product launches or line changes.
Extended audit closure timelines.

Verifying accreditation scopes before commissioning critical studies is one of the simplest, highest-value controls in any phased plan.

Governance and Accountability for a 24-Month Roadmap

Even a well-sequenced list of studies will drift without governance. The structure does not need to be complex, but roles and cadence must be explicit.

Who Owns What

QA and food safety
Own the technical content of the roadmap. This includes risk ranking, identification of required studies, choice of methods, and selection of qualified labs. They are also responsible for aligning designs with CFIA, Health Canada, and applicable GFSI scheme expectations.
Operations
Own plant access, resource scheduling, and integration of studies into production plans. Kill step trials, packaging changes for shelf life work, and EMP remapping all consume line time and staff. Without operations ownership, studies get bumped every time production is tight.
Finance
Own budget integration and capital allocation. They need forward visibility into Tier 3 spend, an understanding of the risk logic, and a way to connect program maturity to risk and insurance discussions.

A steering group with representation from these three functions, meeting at least quarterly, is typically enough to keep a 24 month plan on track.

Review and Revalidation Triggers

At least once a year, leadership should review whether any of the following have occurred:

New or updated regulatory guidance that affects validated processes.
Customer requirement changes related to documentation, methods, or sampling.
Significant changes in formulation, equipment, throughput, or process parameters.
New scientific information on relevant pathogens, surrogates, or technologies.
Audit findings or incidents that challenge prior validation assumptions.

The outcome of that review should be documented, even if it is simply a brief record that no revalidation is required for specific processes in the coming year. That record becomes part of the defensibility package in future audits.

Budgeting for a Standing Program

By the end of a 24 month phasing period, the testing and validation budget should have two visible components:

A standing program line for routine Tier 1 and Tier 2 work, EMP operation, lab service agreements, and annual reviews.
A variable validation line for Tier 3 studies tied to the gap register and revalidation triggers.

In stable years, the variable line will be lower and can focus on targeted improvements or new products. In years with major changes or regulatory updates, it will rise. Presenting it this way helps finance teams treat validation as a managed risk investment rather than a series of unplanned charges.

A Practical 24-Month Phasing Framework

Each plant’s roadmap will look different, but most mid-sized manufacturers can benefit from a simple four-phase structure.

Phase 1 (Months 1 to 6): Assess and Stabilize

Focus:

Map products and processes to risk tiers.
Conduct a structured gap assessment against CFIA, Health Canada, and key customer expectations.
Inventory existing studies, methods, and lab relationships, including accreditation scopes.
Establish or refine EMP baseline data for high-risk zones.
Consolidate lab work where it makes sense, prioritising ISO 17025 accredited partners for Tier 3 needs.

Outcome:

A risk-ranked gap register.
A prioritized list of Tier 3 studies for high-hazard products.
Clarity on which lab partners can support which elements of the roadmap.

Phase 2 (Months 7 to 12): Validate High-Risk Controls

Focus:

Commission kill step validation for high-risk thermal processes, especially in low-moisture and RTE categories where Salmonella or Listeria risks are material.
Run microbial challenge or shelf life studies for priority SKUs, especially where existing shelf life claims lack accredited data.
Validate pH and water activity hurdles for acidified, fermented, and extended shelf life products.
Initiate ICMSF-style sampling plan reviews for high-volume lines, using early EMP and process data.

Outcome:

Confidence that the highest consequence hazards have current, accredited validation.
Early evidence that can be used with regulators, auditors, and key customers.

Phase 3 (Months 13 to 18): Optimise the Operating Model

Focus:

Analyse which routine tests might be better moved in-house based on volume, turnaround needs, and available expertise.
Decide which work should remain with external ISO 17025 labs for independence, advanced methods, or regulatory reasons.
Refine EMP design using trend data from the first year, including frequency adjustments and intensified sampling where needed.
Integrate validation and verification data into simple dashboards that operations and QA can use in monthly performance reviews.

Outcome:

A clearer division of labour between internal and external testing.
Reduced duplication and better alignment of EMP effort with actual risk.
Data that supports both day-to-day decisions and strategic discussions.

Phase 4 (Months 19 to 24): Embed Metrics and Reinvestment Cycles

Focus:

Finalise dashboards that bring together holds, complaints, positives, audit findings, and key testing metrics.
Formalise revalidation triggers and the annual review process in written procedures.
Align the next 12 month validation portfolio with capital planning and customer roadmaps.
Package program performance for leadership, insurers, and prospective buyers or investors, focusing on risk reduction and defensibility rather than vanity metrics.

Outcome:

Validation and testing firmly positioned as part of the core management system, not an ad hoc set of projects.
A repeatable, explainable planning cycle for future years.

Financial Logic and Risk-Adjusted Returns

Framed correctly, testing and validation are not simply QA costs. They are a form of proactive risk financing.

The comparison that tends to resonate inside boardrooms is between:

A known, budgetable annual cost for a structured testing and validation program.
The uncertain, potentially very large cost of recalls, licence actions, lost customers, and legal or insurance exposures that an underinvested program makes more likely.

The program cannot eliminate risk. What it can do is:

Reduce the likelihood of specific adverse events.
Reduce the severity of those events when they occur.
Improve the organisation’s position in regulatory, customer, and legal forums by demonstrating that reasonable, science-based controls were in place.

Examples:

A validated kill step with accredited data lowers the chance that a pathogen challenge to a process will succeed during a CFIA inspection or a liability claim.
A robust EMP with documented trend analysis gives earlier warning of Listeria issues in post-process areas, making it more likely that corrective actions will occur before contaminated product reaches market.
Shelf life validations that include abuse conditions reduce the chance of label-related recalls and the penalties that follow.
Consolidated lab relationships with consistent methods reduce the chance of data being challenged or rejected in audits, avoiding repeat work and extended closure timelines.
Documented revalidation triggers reduce the chance that a process change quietly invalidates prior studies.

From a finance perspective, the key is not to argue that testing and validation pay for themselves in every scenario. It is to show that, relative to the exposures they manage, these investments offer sensible, risk-adjusted returns.

Short Scenarios: How Phasing Works in Practice

Scenario 1: Dry Snack Facility with Aging Roasters

A mid-sized snack plant produces seasoned nuts and extruded snacks for national retailers. Routine finished product testing has been expanded over time, but no formal kill step validation has ever been run on older roasting lines.

Phase 1 identifies Salmonella as the primary hazard and confirms that there is no accredited validation for existing time and temperature settings. Two kill step studies are moved into Phase 2, one for each major line, using an ISO 17025 accredited lab. EMP work confirms that post-roast areas are generally well-controlled but identifies a few drains and floor areas requiring additional cleaning.

By the end of Year 1, the plant has accredited kill step validations, refined EMP frequencies, and a clear record of decision-making. Routine testing volumes are adjusted downward on some low-risk lines, freeing budget to fund the Tier 3 work without increasing total spend.

Scenario 2: Refrigerated RTE Facility with Listeria Concerns

A ready-to-eat facility produces salads and deli items with moderate shelf life. A past Listeria find in a post-process area led to an EMP overhaul, but shelf life studies for several SKUs rely on dated internal work without accredited challenge data.

Phase 1 mapping reveals that the most significant risk is the combination of RTE status, extended shelf life, and shared equipment. Phase 2 investments focus on challenge studies for top SKUs, aligned with the most current Health Canada Listeria policy. EMP design is refined to focus on hard-to-clean equipment surfaces and niche areas that have historically been under-sampled.

In Phase 3, the facility invests in limited in-house indicator testing to speed up decision-making while keeping pathogen work with an accredited external lab. By Phase 4, the team can show auditors and retailers a clear linkage between EMP data, shelf life validation, and corrective actions taken over the prior 24 months.

Scenario 3: Multi-Site Processor Rationalising Lab Spend

A processor with three plants has accumulated relationships with several labs. Each site uses different methods and panels, and senior leadership struggles to understand overall risk or spending.

Phase 1 standardises risk assessment across sites and inventories existing studies. Phase 2 focuses on bringing high-hazard processes across all plants up to a common validation standard with one or two core ISO 17025 partners. Phase 3 then addresses in-house versus external testing decisions, with some high-volume indicator work moved inside and all Tier 3 work consolidated externally.

By the end of 24 months, the group has reduced the number of labs used, harmonised methods, and reallocated a portion of the savings to fund validation work that had been deferred for years.

Frequently Asked Questions from Leadership Teams

How much should a mid-sized food plant allocate to testing and validation each year?

The answer depends on product mix, risk profile, and regulatory exposure. A practical approach is to separate spend into routine verification and EMP costs, which tend to be relatively stable, and Tier 3 validation investments, which will spike in years with major changes. Using a risk-ranked gap register to justify Tier 3 studies gives finance teams a transparent basis for allocation.

Can we safely delay kill step validation until year two?

Delaying high-consequence validation is rarely a good choice once a hazard and process gap are clearly identified. In a phased plan, the better approach is to move routine panel expansions or lower-risk studies to later phases and prioritise kill step work in the first 12 months. If capacity is constrained, you can focus on the highest hazard lines first, but leaving critical lethality questions open for long periods is hard to defend.

What is the practical difference between verification testing and validation in a PCP?

Verification testing checks that controls are working as intended on an ongoing basis. Validation demonstrates that the control, as designed and operated, is capable of achieving the required outcome under defined conditions. Both are required under Preventive Control Plans, but they answer different questions. A structured program makes sure you do not rely on verification data to compensate for missing or outdated validation.

How do we confirm whether our current lab is accredited for the tests we rely on?

Ask for the lab’s current ISO 17025 scope and confirm that the methods, matrices, and analytes used in your critical studies are explicitly listed. Do not rely on generic statements that the lab is “ISO 17025 accredited.” For Tier 3 work, confirm that the methods used align with CFIA, Health Canada, or internationally recognised standards where applicable.

How do we justify increased testing and validation spend after a clean audit?

A clean audit is not evidence that all risks are fully controlled. It is evidence that, at a point in time, the auditor did not identify non-conformances. You can frame increased spend as a way to address known gaps, to keep validation current with regulatory and scientific changes, and to reduce dependence on luck in future audits or investigations.

When does in-house testing make sense versus staying fully external?

In-house testing can make sense for high-volume indicators where rapid turnaround improves decisions and where you can sustain the required competence and quality systems. For pathogens, complex validations, and studies that will be scrutinised by regulators or major customers, external ISO 17025 labs usually remain the better choice, both for competence and perceived independence.

How does this 24-month roadmap align with GFSI schemes and investor expectations?

GFSI-recognised schemes expect documented validation, verification, and management review. A phased roadmap with clear risk logic, accredited methods, and annual review cycles aligns well with those expectations. For investors and buyers, the same roadmap provides evidence that food safety risk is managed systematically rather than informally, which can support better valuations and deal terms.

Turning Phased Validation into a Strategic Advantage

Phasing testing and validation investments over 12 to 24 months is not just about surviving audits. It gives leadership a clear view of where the microbiology and validation budget is going, what risk it is addressing, and how that aligns with regulatory and customer expectations.

The most effective next step for many teams is to commission a structured assessment that maps current testing, EMP, and validation work against product and process risks, then surfaces the highest-consequence gaps. That assessment can then be shaped into a 24 month roadmap the QA, operations, and finance teams can support.

If you want a partner to help you build a phased, compliance-first testing and validation strategy that fits your plants, portfolio, and growth plans, Cremco Labs can work with your team to design and execute a tailored roadmap grounded in ISO 17025 accredited methods and audit-ready documentation.